Do analysts rate COCP or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is COCP or SCLX more profitable?

Cocrystal Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Scilex -1,110.17% N/A -143.55%

Do analysts recommend IMMP or COCP?

Prima BioMed presently has a consensus target price of $5.50, indicating a potential upside of 1,176.40%. Given Prima BioMed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prima BioMed is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, IMMP or COCP?

Cocrystal Pharma has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $4.08M 15.56 -$39.78M N/A N/A Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A

Is IMMP or COCP more profitable?

Prima BioMed's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Cocrystal Pharma N/A -150.61% -97.86%

Do analysts recommend COCP or KALA?

KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 57,133.15%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, COCP or KALA?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is COCP or KALA more profitable?

Cocrystal Pharma's return on equity of -150.61% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% KALA BIO N/A -1,336.10% -94.85%

Do analysts rate COCP or FLNA?

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 300.00%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, COCP or FLNA?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is COCP or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Cassava Sciences N/A -53.90% -34.20%

Do analysts recommend COCP or HYPD?

Hyperion DeFi has a consensus price target of $6.95, suggesting a potential upside of 121.34%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hyperion DeFi 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is COCP or HYPD more profitable?

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Hyperion DeFi N/A -91.59% -73.08%

Cocrystal Pharma (COCP) Competitors

$1.05 0.00 (0.00%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$1.05 0.00 (0.00%)

As of 06:12 AM Eastern

Compare

COCP vs. SCLX, IMMP, KALA, FLNA, and HYPD

Should you buy Cocrystal Pharma stock or one of its competitors? MarketBeat compares Cocrystal Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cocrystal Pharma include Scilex (SCLX), Prima BioMed (IMMP), KALA BIO (KALA), Cassava Sciences (FLNA), and Hyperion DeFi (HYPD). These companies are all part of the "pharmaceutical products" industry.

How does Cocrystal Pharma compare to Scilex?

Cocrystal Pharma (NASDAQ:COCP) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Cocrystal Pharma has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has higher earnings, but lower revenue than Scilex. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Scilex	$30.25M	2.21	-$358.73M	-$40.47	N/A

In the previous week, Cocrystal Pharma had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat Cocrystal Pharma's score of 0.43 indicating that Scilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Scilex	Positive

Cocrystal Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Scilex	-1,110.17%	N/A	-143.55%

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cocrystal Pharma and Scilex tied by winning 6 of the 12 factors compared between the two stocks.

How does Cocrystal Pharma compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Prima BioMed presently has a consensus target price of $5.50, indicating a potential upside of 1,176.40%. Given Prima BioMed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prima BioMed is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Prima BioMed has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Prima BioMed had 6 more articles in the media than Cocrystal Pharma. MarketBeat recorded 8 mentions for Prima BioMed and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.43 beat Prima BioMed's score of 0.17 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Prima BioMed	Neutral
Cocrystal Pharma	Neutral

Cocrystal Pharma has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$4.08M	15.56	-$39.78M	N/A	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Prima BioMed's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Cocrystal Pharma	N/A	-150.61%	-97.86%

Summary

Prima BioMed beats Cocrystal Pharma on 8 of the 12 factors compared between the two stocks.

How does Cocrystal Pharma compare to KALA BIO?

Cocrystal Pharma (NASDAQ:COCP) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cocrystal Pharma had 1 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Cocrystal Pharma's score of 0.43 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
KALA BIO	Very Positive

Cocrystal Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 57,133.15%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cocrystal Pharma has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

Cocrystal Pharma's return on equity of -150.61% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

KALA BIO beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Cassava Sciences?

Cocrystal Pharma (NASDAQ:COCP) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 300.00%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

In the previous week, Cocrystal Pharma had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.87 beat Cocrystal Pharma's score of 0.43 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Cassava Sciences	Very Positive

Cocrystal Pharma has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Cassava Sciences	N/A	-53.90%	-34.20%

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cassava Sciences beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Hyperion DeFi?

Cocrystal Pharma (NASDAQ:COCP) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Cocrystal Pharma has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, indicating that its share price is 149% more volatile than the broader market.

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Hyperion DeFi	N/A	-91.59%	-73.08%

Cocrystal Pharma has higher earnings, but lower revenue than Hyperion DeFi. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Hyperion DeFi	$810K	58.77	-$45.31M	-$9.95	N/A

In the previous week, Hyperion DeFi had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Hyperion DeFi and 2 mentions for Cocrystal Pharma. Hyperion DeFi's average media sentiment score of 1.21 beat Cocrystal Pharma's score of 0.43 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Hyperion DeFi	Positive

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hyperion DeFi has a consensus price target of $6.95, suggesting a potential upside of 121.34%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Hyperion DeFi beats Cocrystal Pharma on 11 of the 14 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.48M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.14%
P/E Ratio	-1.44	21.28	27.42	25.27
Price / Sales	N/A	342.11	537.75	100.70
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	2.28	8.71	11.03	6.62
Net Income	-$8.83M	$23.87M	$3.57B	$336.83M
7 Day Performance	3.96%	4.34%	2.91%	3.25%
1 Month Performance	N/A	6.62%	3.73%	0.92%
1 Year Performance	-30.42%	61.64%	34.42%	27.62%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	0.4706 of 5 stars	$1.05 flat	N/A	-29.5%	$14.48M	N/A	N/A	10
SCLX Scilex	0.8293 of 5 stars	$6.88 +0.1%	N/A	+30.5%	$58.41M	$30.25M	N/A	80
IMMP Prima BioMed	1.8259 of 5 stars	$0.39 +4.4%	$5.50 +1,296.3%	-73.9%	$58.05M	$4.08M	N/A	2,021
KALA KALA BIO	3.139 of 5 stars	$3.12 -11.9%	$1,018.75 +32,552.2%	-99.3%	$58.00M	N/A	N/A	30	Positive News
FLNA Cassava Sciences	2.4809 of 5 stars	$1.19 -4.0%	$5.00 +320.2%	-32.4%	$57.49M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. SCLX, IMMP, KALA, FLNA, and HYPD

How does Cocrystal Pharma compare to Scilex?

Summary

How does Cocrystal Pharma compare to Prima BioMed?

Summary

How does Cocrystal Pharma compare to KALA BIO?

Summary

How does Cocrystal Pharma compare to Cassava Sciences?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. SCLX, IMMP, KALA, FLNA, and HYPD

How does Cocrystal Pharma compare to Scilex?

Which has more volatility & risk, COCP or SCLX?

Do analysts rate COCP or SCLX?

Which has preferable earnings & valuation, COCP or SCLX?

Does the media favor COCP or SCLX?

Is COCP or SCLX more profitable?

Do insiders & institutionals have more ownership in COCP or SCLX?

Summary

How does Cocrystal Pharma compare to Prima BioMed?

Do insiders and institutionals believe in IMMP or COCP?

Do analysts recommend IMMP or COCP?

Which has more risk and volatility, IMMP or COCP?

Does the media prefer IMMP or COCP?

Which has higher valuation & earnings, IMMP or COCP?

Is IMMP or COCP more profitable?

Summary

How does Cocrystal Pharma compare to KALA BIO?

Do institutionals & insiders have more ownership in COCP or KALA?

Does the media favor COCP or KALA?

Which has higher valuation and earnings, COCP or KALA?

Do analysts recommend COCP or KALA?

Which has more volatility and risk, COCP or KALA?

Is COCP or KALA more profitable?

Summary

How does Cocrystal Pharma compare to Cassava Sciences?

Do analysts rate COCP or FLNA?

Which has higher earnings and valuation, COCP or FLNA?

Does the media refer more to COCP or FLNA?

Which has more risk & volatility, COCP or FLNA?

Is COCP or FLNA more profitable?

Do institutionals & insiders believe in COCP or FLNA?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Which has more volatility and risk, COCP or HYPD?

Is COCP or HYPD more profitable?

Which has better valuation & earnings, COCP or HYPD?

Does the media favor COCP or HYPD?

Do insiders and institutionals have more ownership in COCP or HYPD?

Do analysts recommend COCP or HYPD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools